Pouyan N, Younesi Sisi F, Kargar A, Scheidegger M, McIntyre R, Morrow J. The effects of lysergic acid diethylamide (LSD) on the positive valence systems: A Research Domain Criteria (RDoC)-informed systematic review. CNS Drugs. 2023;37:12. https://doi.org/10.1007/s40263-023-01044-1.

Google Scholar 

Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. Psychedelics and the essential importance of context. J Psychopharmacol. 2018;32:725–31.

Article  PubMed  Google Scholar 

Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, et al. The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology. 2018;235:505–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22:603–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaelen M, Barrett FS, Roseman L, Lorenz R, Family N, Bolstridge M, et al. LSD enhances the emotional response to music. Psychopharmacology. 2015;232:3607–14.

Article  CAS  PubMed  Google Scholar 

Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cereb Cortex. 2018;28:3939–50.

Article  PubMed  Google Scholar 

Adamska I, Finc K. Effect of LSD and music on the time-varying brain dynamics. Psychopharmacology. 2023;240:1601–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friesen P. Psychosis and psychedelics: historical entanglements and contemporary contrasts. Transcult Psychiatry. 2022;59:592–609.

Article  PubMed  PubMed Central  Google Scholar 

Hoch PH. Remarks on LSD and mescaline. J Nerv Ment Dis. 1957;125:442.

Article  CAS  PubMed  Google Scholar 

Deshon HJ, Rinkel M, Solomon HC. Mental changes experimentally produced by L. S. D. (d-Lysergic acid diethylamide tartrate). Psych Q. 1952;26:33–53.

Article  CAS  Google Scholar 

Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J Psychopharmacol. 2019;33:1076–87.

Article  PubMed  Google Scholar 

Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. 2011;218:649–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016;30:1259–67.

Article  CAS  PubMed  Google Scholar 

Garel N, Drury J, Thibault Lévesque J, Goyette N, Lehmann A, Looper K, et al. The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Front Psychiatry. 2023;14:1268832.

Article  PubMed  PubMed Central  Google Scholar 

Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11:125–36.

Article  CAS  PubMed  Google Scholar 

van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the Clinician Administered Dissociative State Scale. J Affect Disord. 2018;227:11–6.

Article  PubMed  Google Scholar 

Ballard ED, Zarate CA. The role of dissociation in ketamine’s antidepressant effects. Nat Commun. 2020;11:6431.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend. 2014;136:153–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of Consciousness Rating Scale (OAV). PLoS ONE. 2010;5:e12412.

Article  PubMed  PubMed Central  Google Scholar 

D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol. 2004;29:1558–72.

Article  Google Scholar 

van Heugten-Van der Kloet D, Giesbrecht T, van Wel J, Bosker WM, Kuypers KP, Theunissen EL, et al. MDMA, cannabis, and cocaine produce acute dissociative symptoms. Psychiatry Research. 2015;228:907–12.

Sanches RF, De Lima OF, Dos Santos RG, Macedo LRH, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36:77–81.

Article  CAS  PubMed  Google Scholar 

Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry. 2019;10:650.

Article  PubMed  PubMed Central  Google Scholar 

Holze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology. 2019;45:462–71.

Article  PubMed  PubMed Central  Google Scholar 

Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience. 2007;146:509–14.

Article  CAS  PubMed  Google Scholar 

Edsinger E, Dölen G. A conserved role for serotonergic neurotransmission in mediating social behavior in octopus. Curr Biol. 2018;28:3136-3142.e4.

Article  CAS  PubMed  Google Scholar 

Molla H, Lee R, Lyubomirsky S, de Wit H. Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations. Sci Rep. 2023;13:15846.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol. 1993;33:639–76.

Article  CAS  PubMed  Google Scholar 

Bedi G, Hyman D, de Wit H. Is ecstasy an “empathogen”? effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiat. 2010;68:1134–40.

Article  CAS  PubMed  Google Scholar 

Corbin WR, Hartman JD, Bruening AB, Fromme K. Contextual influences on subjective alcohol response. Exp Clin Psychopharmacol. 2021;29:48–58.

Article  PubMed  Google Scholar 

Alboni S, van Dijk RM, Poggini S, Milior G, Perrotta M, Drenth T, et al. Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol Psychiatry. 2017;22:552–61.

Article  CAS  PubMed  Google Scholar 

Gerevich J, Bácskai E, Farkas L, Danics Z. A case report: pavlovian conditioning as a risk factor of heroin “overdose” death. Harm Reduct J. 2005;2:11.

Article  PubMed  PubMed Central  Google Scholar 

Siegel S. The heroin overdose mystery. Curr Dir Psychol Sci. 2016;25:375–9.

Article  Google Scholar 

O’Brien CP, Childress AR, McLellan AT, Ehrman R. A learning model of addiction. Res Publ Assoc Res Nerv Ment Dis. 1992;70:157–77.

PubMed  Google Scholar 

Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F, Lee Y, Rosenblat JD, Teopiz KM, et al. A Research Domain Criteria (RDoC)-guided dashboard to review psilocybin target domains: a systematic review. CNS Drugs. 2022;36:1031–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hartogsohn I. American trip: set, setting, and the psychedelic experience in the twentieth century. New York: MIT Press; 2020.

Book  Google Scholar 

Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry. 2016;3:619–27.

Article  PubMed  Google Scholar 

Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et al. Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension. JAMA. 2022;328:2252–64.

Article  PubMed  Google Scholar 

Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348: g1687.

Article